At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

The outbreak occurred in a flock of 190 backyard poultry birds in the district of Birzgales, Paris-based WOAH said in a notice, citing Latvian authorities. Vera shares skyrocket as kidney disease drug ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Merck’s combo of KEYTRUDA and Trodelvy reduces disease progression or death risk by 35% in tough-to-treat breast cancer.

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...